Treatment of atypical depression with cognitive therapy or phenelzine: A double-blind, placebo-controlled trial

Archives of General Psychiatry

Volumn 56, Issue 5, 1999, Pages 431-437

  Jarrett, Robin B ^a   Schaffer, Martin ^a   McIntire, Donald ^a   Witt Browder, Amy ^a   Kraft, Dolores ^a   Risser, Richard C ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); MONOAMINE OXIDASE INHIBITOR; PHENELZINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DROWSINESS; FATIGUE; FEMALE; HAMILTON SCALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; XEROSTOMIA;

ADULT; AMBULATORY CARE; ANALYSIS OF VARIANCE; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MONOAMINE OXIDASE INHIBITORS; PHENELZINE; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0032961185     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.56.5.431     Document Type: Article

References (37)

1. Liebowitz MR, Quitkin FM, Stewart JW, McGrath PJ, Harrison W, Rabkin JG, Tricamo E, Markowitz JS, Klein OF. Phenelzine vs imipramine in atypical depression: a preliminary report. Arch Gen Psychiatry. 1984;41:669-677.
2. Liebowitz MR, Quitkin FM, Stewart JW, McGrath PJ, Harrison WM, Markowitz JS, Rabkin JG, Tricamo E, Goetz DM, Klein DF. Antidepressant specificity in atypical depression. Arch Gen Psychiatry. 1988;45:129-137.
3. Thase ME, Trivedi MH, Rush AJ. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology. 1995;12:185-219.
4. McGrath PJ, Stewart JW, Nunes EV, Ocepek-Welikson K, Rabkin JG, Quitkin FM, Klein DF. A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression. Am J Psychiatry. 1993;150: 118-123.
5. Quitkin FM, McGrath PJ, Stewart JW, Harrison WM, Tricamo E, Wager SG, Ocepek-Welikson K, Nunes E, Rabkin JG, Klein DF. Atypical depression, panic attacks, and response to imipramine and phenelzine: a replication. Arch Gen Psychiatry. 1990;47:935-941.
6. Quitkin FM, Harrison W, Stewart JW, McGrath PJ, Tricamo E, Ocepek-Welikson K, Rabkin JG, Wager SG, Nunes E, Klein DF. Response to phenelzine and imipramine in placebo nonresponders with atypical depression: a new application of the crossover design. Arch Gen Psychiatry. 1991;48:319-323.
7. Quitkin FM, Stewart JW, McGrath PJ, Tricamo E, Rabkin JG, Ocepek-Welikson IK, Nunes E, Harrison W, Klein DF. Columbia atypical depression: a subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. Br J Psychiatry. 1993;163(suppl 21):30-34.
8. Clinical Practice Guideline Number 5: Depression In Primary Care, 2: Treatment of Major Depression. Rockville, Md: Agency for Health Care Policy and Research, US Dept of Health and Human Services; 1993. AHCPR publication 93-0551.
9. Kasper S, Lepine JP, Mendlewlcz J, Montgomery SA, Rush AJ. Efficacy, safety, and indications for tricyclics and newer antidepressants. Depression. 1995;2: 127-137.
10. Reimherr FW, Wood DR, Byeriey B, Brainard J, Grosser BI. Characteristics of responders to fluoxetine. Psychopharmacol Bull. 1984;20:70-72.
11. Pande AC, Birkett M, Fechner-Bates S, Haskett RF, Greden JF. Fluoxetine versus pherelzine in atypical depression. Biol Psychiatry. 1996;40:1017-1020.
12. Hollon SD, DeRubeis RJ, Evans MD, Wiemer MJ, Garvey MJ, Grove WM, Tuason VB. Cognitive therapy and pharmacotherapy for depression: singly and in combination. Arch Gen Psychiatry. 1992;49:774-781.
13. Jarrett RB, Rush AJ. Short-term psychotherapy of depressive disorders: current status and future directions. Psychiatry. 1994;57:115-132.
14. Mercier MA, Stewart JW, Quitkin FM. A pilot sequential study of cognitive therapy and pharmacotherapy of atypical depression. J Clin Psychiatry. 1992;53:166-170.
15. Robinson LA, German JS, Neimeyer RA. Psychotherapy for the treatment of depression: a comprehensive review of controlled outcome research. Psychol Bull. 1990;106:30-49.
16. Blackburn IM, Bishop S, Glen AIM, Whalley LJ, Christie J. The efficacy of cognitive therapy in depression: a treatment trial using cognitive therapy and pharmacotherapy, each alone and in combination. Br J Psychiatry. 1981;139:181-189.
17. Elkin I, Shea MT, Watkins JT, Imber SD, Sotsky SM, Collins JF, Glass DR, Pilkonis PA, Leber WR, Docherty JP, Fiester SJ, Parloff MB. National Institute of Mental Health Treatment of Depression Collaborative Research Program: general effectiveness of treatments. Arch Gen Psychiatry. 1989;46:971-982.
18. McKnight DL, Nelson-Gray RO, Barnhill J. Dexamethasone suppression test and response to cognitive therapy and antidepressant medication. Behav Ther. 1992; 23:99-111.
19. Murphy GE, Simons AD, Wetzel RD, Lustman PJ. Cognitive therapy and pharmacotherapy: singly and together in the treatment of depression. Arch Gen Psychiatry. 1984;41:33-41.
20. Beutler LE, Scogin F, Kirkish P, Schretlen D, Corbishley A, Hamblin D, Meredith K, Potter R, Bamford CR, Levenson AI. Group cognitive therapy and alprazolam in the treatment of depression in older adults. J Consult Clin Psychol. 1987;55: 550-556.
21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
22. Spitzer RL, Williams JBW, Gibbon M, First MB. Structured Clinical Interview for DSM-III-R. New York, NY: New York State Psychiatric Institute, Biometrics Research Department; 1989.
23. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition. Washington, DC: American Psychiatric Association; 1987.
24. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 12:56-62.
25. Spitzer RL, Endicott J, Robins E. Research Diagnostic Criteria: rationale and reliability. Arch Gen Psychiatry. 1978;35:773-782.
26. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition. Washington, DC: American Psychiatric Association; 1980.
27. Winokur G, Behar D, Van Valkenberg C, Lowry, M. Is a familial definition of depression both feasible and valid? J Nerv Ment Dis. 1978;166:764-768.
28. Winokur G. Familial (genetic) subtypes of pure depressive disease. Am J Psychiatry. 1979;136:911-913.
29. Beck AT, Rush AJ, Shaw B, Emery G. Cognitive Therapy of Depression. New York, NY: Guilford Press; 1979.
30. Vallis TM, Shaw BF, Dobson KD. The Cognitive Therapy Scale: psychometric properties. J Consult Clin Psychol. 1986;54:381-385.
31. Young J, Beck AT. Cognitive Therapy Scale: Rating Manual. Philadelphia, Pa: Center for Cognitive Therapy; 1980.
32. Schaffer M, Kobes R, Krebaum S, Basco MR. Atypical Depression: Treatment in the Medication Clinic. Dallas, Tex: University of Texas Southwestern Medical Center; 1990.
33. Fawcett J, Epstein P, Feister S, Elkin I, Autry J. Clinical management-imipiamine/ placebo administration manual: NIMH Treatment of Depression Collaboration Research Program. Psychopharmacol Bull. 1987;23:309-324.
34. Robinson DS, Nies A, Ravaris CL, Ives JO, Bartlett D. Clinical pharmacology of pherelzine. Arch Gen Psychiatry. 1978;35:629-635.
35. Orsulak PJ, Wittman PD, Akers LC. Evaluation of and HPLC assay for monitoring monoamine oxidase (MAO) inhibition in human platelets and plasma [abstract]. Clin Chem. 1991;37:999.
36. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561-571.
37. Guy W. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: Dept of Health and Human Services; 1976. Publication ADM 76-338.